Scholars@Duke publication: Population pharmacokinetics (PK) and pharmacodynamics (PD) of integrelin, a platelet aggregation inhibitor

Population pharmacokinetics (PK) and pharmacodynamics (PD) of integrelin, a platelet aggregation inhibitor

Publication , Journal Article

Sambol, NC; Tcheng, JE; Kitt, M; Lorenz, T

Published in: CLINICAL PHARMACOLOGY & THERAPEUTICS

February 1, 1996

CLINICAL PHARMACOLOGY & THERAPEUTICS

0009-9236

February 1, 1996

PI84 / PI84

MOSBY-YEAR BOOK INC

APA

Chicago

ICMJE

MLA

NLM

Sambol, N. C., Tcheng, J. E., Kitt, M., & Lorenz, T. (1996). Population pharmacokinetics (PK) and pharmacodynamics (PD) of integrelin, a platelet aggregation inhibitor. CLINICAL PHARMACOLOGY & THERAPEUTICS, 59(2), PI84–PI84.

Sambol, N. C., J. E. Tcheng, M. Kitt, and T. Lorenz. “Population pharmacokinetics (PK) and pharmacodynamics (PD) of integrelin, a platelet aggregation inhibitor.” CLINICAL PHARMACOLOGY & THERAPEUTICS 59, no. 2 (February 1, 1996): PI84–PI84.

Sambol NC, Tcheng JE, Kitt M, Lorenz T. Population pharmacokinetics (PK) and pharmacodynamics (PD) of integrelin, a platelet aggregation inhibitor. CLINICAL PHARMACOLOGY & THERAPEUTICS. 1996 Feb 1;59(2):PI84–PI84.

Sambol, N. C., et al. “Population pharmacokinetics (PK) and pharmacodynamics (PD) of integrelin, a platelet aggregation inhibitor.” CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 59, no. 2, MOSBY-YEAR BOOK INC, Feb. 1996, pp. PI84–PI84.

CLINICAL PHARMACOLOGY & THERAPEUTICS

0009-9236

February 1, 1996

PI84 / PI84

MOSBY-YEAR BOOK INC